Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02870231 · ClinicalTrials.gov registry record · Phase 1
Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male and Female Subjects Being Overweight or With Obesity
A Phase 1 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 187
- Enrollment target
NCT02870231 is a Phase 1 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 187 participants.
The verdict
NCT02870231, a Phase 1 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 187 participants
- Enrollment target
Study Summary
This trial is conducted in the United States of America. The aim of this trial is to investigate Safety, Tolerability, PK (the exposure of the trial drug in the body) and PD (the effect of the investigated drug on the body) for Multiple Doses of NNC9204-0530 in Combination with Liraglutide in Male and Female Subjects being Overweight or with Obesity
Interventions
- DRUG placebo
- DRUG liraglutide
- DRUG NNC9204-0530
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 187 participants |
| Start Date | 2016-08-18 |
| Est. Completion | 2017-09-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02870231
The ClinicalTrials.gov registry entry for NCT02870231 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 187 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT02870231 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02870231 about?
NCT02870231 is a clinical study titled "Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male and Female Subjects Being Overweight or With Obesity". This trial is conducted in the United States of America. The aim of this trial is to investigate Safety, Tolerability, PK (the exposure of the trial drug in the body) and PD (the effect of the investigated drug on the body) for Multiple Doses of NNC9204-0530 in Combination with Liraglutide in Male a...
What is the current status of trial NCT02870231?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 187 participants. The study started on 2016-08-18. Estimated completion is 2017-09-03.
What interventions are being tested in trial NCT02870231?
The interventions under investigation include: placebo (DRUG), liraglutide (DRUG), NNC9204-0530 (DRUG).
Who is sponsoring clinical trial NCT02870231?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.